Due to the absence of a therapeutic target (endocrine therapy targets the ER and PR, and trastuzumab targets HER2), the prognosis of patients with TNBC is poorer than that of patients with other types of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.